Navigation Links
DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
Date:4/18/2013

New York, NY (PRWEB) April 18, 2013

The drug safety advocates at DrugRisks.com are alerting of updated legal news on the site for patients who have taken the diabetes drug Actos. A jury could begin deliberations today in a trial accusing Takeda Pharmaceuticals of causing bladder cancer with their diabetes drug Actos***.

DrugRisks is designed to improve the safety of those taking popular prescription drugs like Actos by providing the latest warnings, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

The FDA and European Medicines Agency* have warned that taking Actos for longer than one year may be associated with an increased risk of bladder cancer. Regulators in France and Germany have even banned its use**.

DrugRisks has learned as many as 3,000 patients in the U.S. have filed an Actos lawsuit against Takeda Pharmaceuticals over allegations their drug caused bladder cancer***. The first trial is underway for Jack Cooper, a grandfather who is now terminally ill from the disease***.

Now, the resource center has added legal news showing lawyers are finishing their closing arguments and the jury could begin deliberations as soon as Tuesday or Wednesday this week. A decision is expected soon***.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-04-15/takeda-s-actos-diabetes-drug-tied-to-cancer-jury-is-told.html

Read the full story at http://www.prweb.com/releases/actos-lawsuit-news-2013/settlement-update/prweb10639079.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
2. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
3. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
4. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
5. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
6. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
7. Nia Vardalos Speaks Out on Adoption, Bolsters Legal Support for Abused Children
8. Tariq Drabu Supports Latest Campaign Against Illegal Tooth Whitening
9. Best Injury Lawyers? Time Magazine Includes McDonaldWorley.com Among Nations Legal Leaders
10. Gun retailers take a hard line on illegal firearm sales, UC Davis survey finds
11. Yasmin Blood-Clotting Lawsuits Update: Resource4thePeople Providing Legal Assistance as Concerns Rise Over Health Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 29, 2017 , ... The ... Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, ... questions regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
Breaking Medicine Technology: